| P/E (FY) | 23.5 | Sales (TTM) | €1.20B |
| Earnings (TTM) | €155.6M | ROE | 9.19% |
| Net Margin | 13.02% | ROIC | 11.31% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | −11.77% | Sales Growth 3Y | −4.24% |
DiaSorin S.p.A. conducts research and development and manufactures and distributes immunodiagnostic and molecular diagnostic testing kits in Europe, North America, and internationally. Its immunodiagnostic tests, offered under the LIAISON XL and LIAISON XS names, cover areas such as infectious and gastrointestinal diseases, hepatitis, endocrinology, metabolic disorders, and oncology. The company also provides molecular assays including Simplexa and LIAISON PLEX, and an xMAP technology platform. It is based in Saluggia, Italy.
| Market Cap | $4.06B | Trading Days | 4150 |
| 52W High | 92.32 |
| 52W Low | 52.34 |
| % Off High | −23.51% |
| YTD | 2.91% | 1Y | −21.72% |
| 3Y | −28.59% | 5Y | −56.50% |
| 10Y | 39.77% | Since incept. (ann.) | 8.05% |
| Ann. Volatility (1Y) | 39.59% | Ann. Volatility (3Y) | 31.76% |
| Sharpe (1Y) | −0.45 | Sharpe (3Y) | −0.21 |
| Max Drawdown (1Y) | −38.51% | Max Drawdown (3Y) | −49.02% |
| Beta (3Y, vs SPY) | 0.64 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CELC | Celcuity Inc. | $4.02B | — |
| DBVT | DBV Technologies S.A. | $4.00B | — |
| ICUI | ICU MEDICAL INC/DE | $4.14B | 5525.8 |
| CON | Concentra Group Holdings Parent, Inc. | $4.18B | 25.1 |
| VKTX | Viking Therapeutics, Inc. | $3.93B | — |
| IRTC | iRhythm Holdings, Inc. | $3.86B | — |
| TNGX | Tango Therapeutics, Inc. | $3.85B | — |
| CPRX | CATALYST PHARMACEUTICALS, INC. | $3.85B | 18.7 |
| DNLI | Denali Therapeutics Inc. | $3.82B | — |
| EWTX | Edgewise Therapeutics, Inc. | $4.34B | — |
| LFST | LifeStance Health Group, Inc. | $4.36B |
| — |
| NVST | Envista Holdings Corp | $4.39B | 96.3 |
